Back
Compare AU
Compare DRUG vs. UYLD
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Global X S&P 500 Covered Call Complex ETF (UYLD). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | UYLD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 7 |
Median incremental investment | $745.07 | $1,100.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,035.50 | $3,521.76 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | UYLD | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | UYLD.AX was created on 2023-01-30 by Global X. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Cboe S&P 500 BuyWrite Index. |
Top 3 holdings | KRW - KOREAN WON (0 %) USD - UNITED STATES DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) | NVIDIA Corp (7.64 %) Apple Inc (6.59 %) Microsoft Corp (5.86 %) |
Top 3 industries | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) | Information Technology (62.88 %) Consumer Discretionary (14.80 %) Communication Services (13.64 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (99.39 %) Switzerland (0.28 %) Netherlands (0.13 %) |
Management fee | 0.57 % | 0.6 % |
Key Summary
DRUG | UYLD | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | CBOE S&P 500 BuyWrite Index |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.6 % |
Price | $8.82 | $10.97 |
Size | $184.650 million | $13.322 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.92 % | 6.36 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 31/01/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | UYLD | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 72 | 7 |
Median incremental investment | $745.07 | $1,100.00 |
Median investment frequency | Monthly | Fortnightly |
Median total investment | $2,035.50 | $3,521.76 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | UYLD | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | UYLD |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |